Vipivotide tetraxetan (PSMA-617) is a high-affinity prostate-specific membrane antigen (PSMA) inhibitor (Figure 3) that has recently gained much attention in relation to targeting of prostate cancer metastasis. The gene discussed is FOLH1; the disease is Familial prostate cancer.